ANI Pharmaceuticals (ANIP) rare disease head sells 417 shares under 10b5-1 plan

Rhea-AI Filing Summary

ANI Pharmaceuticals reported that Christopher Mutz, its Head of Rare Disease, sold 417 shares of common stock in an open-market transaction at $74 per share. After this sale, he directly owns 103,508 shares. The sale was made under a pre-established Rule 10b5-1 trading plan adopted by the reporting person.

Insider Trade Summary

Net Seller: 417 shares ($30,858)

Net Sell 1 txn

Insider Mutz Christopher

Role HEAD OF RARE DISEASE

Sold 417 shs ($31K)

Type	Security	Shares	Price	Value
Sale	Common Stock	417	$74.00	$31K

Holdings After Transaction: Common Stock — 103,508 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mutz Christopher

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	HEAD OF RARE DISEASE

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		S(1)		417	D	$74	103,508	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

Remarks:

	/s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ANIP report for Christopher Mutz?

ANI Pharmaceuticals reported that Christopher Mutz sold 417 shares of common stock. The sale occurred in an open-market transaction at $74 per share and was executed under a pre-established Rule 10b5-1 trading plan adopted by the reporting person.

How many ANI Pharmaceuticals (ANIP) shares did the insider sell and at what price?

Christopher Mutz sold 417 ANIP common shares at $74 each. This open-market transaction was reported on Form 4 and was carried out pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in advance of the sale.

How many ANI Pharmaceuticals (ANIP) shares does Christopher Mutz own after the sale?

After the reported sale, Christopher Mutz directly owns 103,508 shares of ANI Pharmaceuticals common stock. This post-transaction ownership figure reflects his remaining direct holdings following the open-market sale of 417 shares executed under a Rule 10b5-1 trading plan.

What is the role of Christopher Mutz at ANI Pharmaceuticals (ANIP)?

Christopher Mutz serves as Head of Rare Disease at ANI Pharmaceuticals. His position is identified in the insider transaction report, which shows his officer status and provides context for the Form 4 filing detailing his recent open-market sale of company shares.

Was the ANIP insider sale by Christopher Mutz under a Rule 10b5-1 plan?

Yes, the sale was made under a Rule 10b5-1 trading plan adopted by Christopher Mutz. The footnote specifies that the plan was established in advance, providing a pre-arranged framework for executing the open-market sale of 417 ANI Pharmaceuticals common shares.